FUNDAMENTALS · Fundamentals · TW Healthcare

Lumosa Therapeutics (6535) Fundamentals 2026 — Revenue Analysis | SniperIQ

Lumosa Therapeutics (6535) is a TW-listed Healthcare company in Biotechnology with a market capitalization of NT

5.0B, trading at NT$89.40 on the TWO. This SniperIQ fundamentals page covers Lumosa Therapeutics's valuation, profitability (net margin -1133.2%), revenue (NT
6M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market CapNT
5.0B
Net Margin-1133.2%
Revenue (FY25)NT
6M

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Lumosa Therapeutics's market cap?

Lumosa Therapeutics (6535) has a market capitalization of approximately NT

5.0B, trading at NT$89.40 on the TWO. Market cap moves with the live share price.

What is Lumosa Therapeutics's P/E ratio?

Lumosa Therapeutics's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 10.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Lumosa Therapeutics?

Lumosa Therapeutics runs a net profit margin of -1133.2%, a gross margin of 58.9%, and an operating margin of -934.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Lumosa Therapeutics generate?

Lumosa Therapeutics reported revenue of NT

6M for fiscal year 2025, with net income of -NT
47M and earnings per share (EPS) of -2.05. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Lumosa Therapeutics pay a dividend?

Lumosa Therapeutics does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Lumosa Therapeutics financially healthy?

Lumosa Therapeutics carries a debt-to-equity ratio of 0.00x and a current ratio of 7.37x, with a market beta of 0.12. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Lumosa Therapeutics a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Lumosa Therapeutics (6535) the key facts are: market cap NT

5.0B, revenue NT
6M, 52-week range 85.8-329.5. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Lumosa Therapeutics's full fundamentals live

Get Lumosa Therapeutics's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.